GlassScriptPhysician profile
Tonja S Shandy
NPI 1235152737
$6,074.55
in general payments reported to CMS, 2019-2025
32 companies · $2,190 in 2025
The $2,190 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $95.67 · 2022: $757 · 2023: $1,323 · 2024: $1,709 · 2025: $2,190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,828 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $300 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,828.05 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $300.00 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $877.26 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $763.04 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $708.23 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $452.58 | 2022-2025 | |
| Amgen INC. | $365.76 | 2022-2025 | Otezla, Repatha, Otezla |
| Glaxosmithkline, LLC. | $344.49 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Tandem Diabetes Care, INC. | $300.00 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $273.08 | 2025 | Caplyta |
| Astellas Pharma US INC | $234.72 | 2022-2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $223.68 | 2022-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $221.87 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $179.29 | 2021-2022 | |
| Abbvie INC. | $168.64 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $168.28 | 2022-2023 | |
| Sumitomo Pharma America, INC. | $140.29 | 2023-2025 | Gemtesa |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $110.88 | 2022-2025 | Austedo Xr, Austedo Xr |
| Exact Sciences Corporation | $100.58 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $65.60 | 2022-2023 | Verquvo, Steglatro, Belsomra |
| Takeda Pharmaceuticals U.S.A., INC. | $65.11 | 2022-2025 | Trintellix |
| Novartis Pharmaceuticals Corporation | $59.90 | 2023-2024 | |
| Otsuka America Pharmaceutical, INC. | $34.49 | 2023 | Nuedexta |
| Phathom Pharmaceuticals, INC. | $33.13 | 2024 | Voquezna |
| Mayne Pharma Commercial LLC | $27.92 | 2024 | |
| Ultragenyx Pharmaceutical INC. | $27.90 | 2023 | |
| Boston Scientific Corporation | $22.99 | 2024 | Wavewriter Alpha Prime 16 |
| Mylan Specialty L.P. | $21.14 | 2024 | Yupelri |
| Viatris Specialty LLC | $18.98 | 2025 | Yupelri |
| Halozyme INC | $17.77 | 2023 | |
| Dexcom, INC. | $15.47 | 2023 | Dexcom G6 Transmitter |
| Biogen, INC. | $15.31 | 2025 | Skyclarys |
| Currax Pharmaceuticals LLC | $13.22 | 2024 | Contrave, Onzetra Xsail |
| Genentech USA, INC. | $2.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tonja Shandy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.